Eprosartan Mesylate

Eprosartan Mesylate

144143-96-4

C24H28N2O7S2

EPROSARTAN MESYLATE, 144143-96-4, Teveten, Eprosartan mesilate, eprosartan methanesulfonate, Eprosartan (mesylate), Eprosartan Monomethanesulfonate, SK&F 108566-J, SK&F-108566-J, 8N2L1NX8S3, DTXSID7044217, CHEBI:48409, (E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid, monomethanesulfonate, 4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid;methanesulfonic acid, Eprosartan mesylate (USAN), DTXCID5024217, EPROSARTAN MESYLATE [USAN], 4-({2-butyl-5-[(1E)-2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; methanesulfonic acid, CAS-144143-96-4, Eprosartan mesylate [USAN:BAN], NCGC00164557-01, UNII-8N2L1NX8S3, Futuran, Navixen, Regulaten, Tevetenz, Epro-sartan mesylate dihydrate, SR-05000001450, Eprosartanmesylate, Teveten SB, SKF-108566J, Teveten (TN), SCHEMBL41396, CHEMBL1200987, HMS3262B17, HMS3885B05, EPROSARTAN MESYLATE [VANDF], EPROSARTAN MESILATE [MART.], Tox21_112186, Tox21_500808, EPROSARTAN MESILATE [WHO-DD], EPROSARTAN MESYLATE [USP-RS], HY-15834A, MFCD08141807, s4102, AKOS015994738, Eprosartan mesylate, >=98% (HPLC), Tox21_112186_1, AM84399, CCG-222112, KS-1233, EPROSARTAN MESYLATE [ORANGE BOOK], NCGC00167505-02, NCGC00261493-01, (E)-4-((2-butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid compound with methanesulfonic acid (1:1), 2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)methylene)-, (E)-, monomethanesulfonate, EPROSARTAN MESYLATE [USP MONOGRAPH], EPROSARTAN MONOMETHANESULFONATE [MI], E-145, E1161, SW219286-1, A13747, D02082, TEVETEN HCT COMPONENT EPROSARTAN MESYLATE, A808180, EPROSARTAN MESYLATE COMPONENT OF TEVETEN HCT, J-007923, SR-05000001450-2, Q27121190, Eprosartan mesylate, United States Pharmacopeia (USP) Reference Standard, (E)-2-BUTYL-1-(P-CARBOXYBENZYL)-.ALPHA.-2-THENYLIMIDAZOLE-5-ACRYLIC ACID, MONOMETHANESULFONATE,

Typically NLT 98%